453 related articles for article (PubMed ID: 16406187)
21. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.
Yu Y; Zhou W; Chen Y; Ding Y; Ma Y
Chin Med J (Engl); 2002 Oct; 115(10):1479-82. PubMed ID: 12490091
[TBL] [Abstract][Full Text] [Related]
23. High incidence of extended-spectrum beta-lactamases among outpatient clinical isolates of Escherichia coli: a phenotypic assessment of NCCLS guidelines and a commercial method.
Sorlózano A; Gutiérrez J; Palanca M; Soto MJ; Piédrola G
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):131-4. PubMed ID: 15474323
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
25. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan.
Liao CH; Sheng WH; Wang JT; Sun HY; Wang HK; Hsueh PR; Chen YC; Chang SC
J Microbiol Immunol Infect; 2006 Feb; 39(1):59-66. PubMed ID: 16440125
[TBL] [Abstract][Full Text] [Related]
26. SHV-5 extended-spectrum beta-lactamases in clinical isolates of Escherichia coli in Malaysia.
Subramaniam G; Palasubramaniam S; Navaratnam P
Indian J Med Microbiol; 2006 Jul; 24(3):205-7. PubMed ID: 16912441
[TBL] [Abstract][Full Text] [Related]
27. Evaluation and updating of the Osiris expert system for identification of Escherichia coli beta-lactam resistance phenotypes.
Bert F; Juvin M; Ould-Hocine Z; Clarebout G; Keller E; Lambert N; Arlet G
J Clin Microbiol; 2005 Apr; 43(4):1846-50. PubMed ID: 15815007
[TBL] [Abstract][Full Text] [Related]
28. [Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli].
Noguera O; Rodríguez JC; López JM; Ruiz M; Royo G
Rev Esp Quimioter; 2009 Mar; 22(1):30-3. PubMed ID: 19308744
[TBL] [Abstract][Full Text] [Related]
29. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.
Wiegand I; Geiss HK; Mack D; Stürenburg E; Seifert H
J Clin Microbiol; 2007 Apr; 45(4):1167-74. PubMed ID: 17287329
[TBL] [Abstract][Full Text] [Related]
30. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
[TBL] [Abstract][Full Text] [Related]
31. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
32. Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia.
Hwang KP; Tang YF; Shen YH
J Microbiol Immunol Infect; 2009 Oct; 42(5):433-8. PubMed ID: 20182674
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of anti-microbial resistance of Escherichia coli that caused infection in urogenital system].
Cui WL; Xu DX; Li WL; Wang LX
Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):940-2, 945. PubMed ID: 15321769
[TBL] [Abstract][Full Text] [Related]
34. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
35. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Bedenic B; Vranes J; Suto S; Zagar Z
Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
[TBL] [Abstract][Full Text] [Related]
36. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain.
Sorlózano A; Gutiérrez J; Salmerón A; Luna JD; Martínez-Checa F; Román J; Piédrola G
Int J Antimicrob Agents; 2006 Dec; 28(6):532-6. PubMed ID: 17045785
[TBL] [Abstract][Full Text] [Related]
37. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
38. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
[TBL] [Abstract][Full Text] [Related]
39. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.
Palasubramaniam S; Muniandy S; Navaratnam P
J Microbiol Immunol Infect; 2009 Apr; 42(2):129-33. PubMed ID: 19597644
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
